Clinical trials: Diabetic Mellitus
- Condition Diabetic Mellitus
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Macular Edema, Macular Degeneration
Study Evaluating Retinal Health Monitoring System Thickness Module
Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).
- Trial name
- NCT04428242
- Testing
- RHMS-RTM, SD-OCT
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Diabetic Kidney Disease
The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer
1. Objective After single dose in healthy adults the capacity of the Group for DW1029M evaluate the pharmacokinetic characteristics. 2. Indication Diabetic kidney disease 3. Efficacy 1.
- Trial name
- NCT02004327
- Testing
- DW1029M300mg, DW1029M600mg, DW1029M1200mg
- Where
- South Korea
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Diabetic Foot Ulcers
A Randomized,Double-blind,Placebo-controlled Clinical Study to Explore the Mechanism of Action of ON101 Cream in Patients With DFUs.
The primary objective is to explore the mechanistic role of ON101 cream in healing diabetic foot ulcers by determining the molecular targets of ON101 cream.
- Trial name
- NCT04945161
- Testing
- ON101 Cream
- Where
- Taiwan
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Oneness Biotech Co., Ltd.
Healthy Adult Participants, Diabetic Kidney Disease
Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439…
- Trial name
- NCT07473323
- Testing
- MTX-439
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Diabetes Mellitus, Ketosis, Diabetic
StatStrip Glucose/Ketone Meter System Ketone Evaluation
The Nova StatStrip Glucose / Ketone Meter System is a fast, simple, whole blood system that can be used to quantify both glucose and ketones using two distinct test strips.
- Trial name
- NCT05118061
- Testing
- Ketone
- Where
- 3 sites in United States, Germany
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Nova Biomedical
Diabetes Mellitus, Type 2, Diabetic Foot
Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure
The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population. The main aims are: 1.
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Foot, Peripheral Arterial Disease, Skin Cancer
- Trial name
- Spectrum1 (NCT06976073)
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Diabetic Foot
BE Study of Metformin GSK 850mg
A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fasting condition.
- Trial name
- BA/BE 198/11 (NCT01710540)
- Testing
- Metformin GSK 850mg, Gluocophage 850mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetic Foot Ulcer, Diabetic Foot
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
The purpose of this clinical investigation is to assess performance of the Medaxis Debritom+™ and to collect subject outcome data in the treatment of diabetic foot ulcers (DFU) vs Standard sharp debridement.
- Trial name
- NCT04564443
- Testing
- Medaxis Debritom+, Sharp Surgical Debridement, Additional Outer Dressing Application
- Where
- 6 sites in United States
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Medaxis, LLC
Type 2 Diabetes Mellitus
Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
Primary Objective: The primary objective of this study is to assess the overall safety of lixisenatide once daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in patients with type 2…
- Trial name
- NCT01940965
- Testing
- lixisenatide AVE0010, biguanide, TZD
- Where
- 27 sites in Japan
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Sanofi
Age-Related Macular Degeneration, Geographic Atrophy
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
To conduct a precision study to assess the microperimetry function of the Spectral OCT/SLO. The study will assess variability across measurements taken by three different operator-device configuration across clinical sites…
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT01692938
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Venous Ulcer, Foot Ulcer, Diabetic
Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers
This study will compare the proportion of patients who have wound closure within 12 weeks as well as the time to wound closure in patients receiving Artacent™ versus standard of care for treatment of non-healing lower extremity…
- Trial name
- TMArtacent (NCT02838784)
- Testing
- Artacent Human Amniotic Membrane, Standard of Care
- Where
- 7 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Tides Medical
Diabetic Foot Ulcer, Ulcer Foot
Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC dressings treatments for Diabetic Foot Wounds
- Conditions
- Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
- Trial name
- NCT03398538
- Testing
- Offloading, Additional (outer) Dressing Application, Mirragen Wound Matrix Dressing
- Where
- 5 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- ETS Wound Care, LLC
Healthy Volunteers and Diabetes Participants
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
- Trial name
- NCT07901595
- Testing
- PAL-119
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Paulex Bio Inc.
Diabetes
Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study
Trigonella Foenum-Graecum, commonly known as Fenugreek, is a plant that has been extensively used as a source of anti-diabetic compounds Fenugreek is traditionally used in India, especially in the Ayurvedic and Unani systems.
- Trial name
- NCT02700477
- Testing
- Fenugreek seeds extract
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Chemical Resources
Diabetic Ulcer
Evaluation of Topical Wound Oxygen (two2) Therapy
The purpose of this study is to evaluate the efficacy of the Topical Wound Oxygen (two2) therapy system on the healing of diabetic lower extremity ulcers.
- Trial name
- NCT00871312
- Testing
- Topical wound oxygen therapy
- Where
- 3 sites in United States, Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- AOTI Ltd.
Diabetic Foot Ulcer, Ulcer Foot
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available treatments for diabetic foot wounds.
- Conditions
- Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
- Trial name
- NCT06403605
- Testing
- Mirragen Advanced Wound Matrix, Fibracol
- Where
- 15 sites in United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- ETS Wound Care, LLC
Diabetes Mellitus
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
The purpose of this study is to evaluate the safety, tolerability, and PK of single oral doses of JTT-252 and the effect of food on the PK of JTT-252 in healthy subjects, and to evaluate the safety, tolerability, PK and PD of…
- Trial name
- NCT02120976
- Testing
- JTT-252
- Where
- 2 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shionogi Inc.
Diabetic Neuropathies
Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy
The study consists of two periods, the Screening Period (~3 weeks) and Treatment Period (12 weeks). Eligibility for the study will be determined by Screening tests, physical examination/medical history, and fulfilment of…
- Trial name
- NCT02435199
- Testing
- EMA401 600mg
- Volunteers
- healthy volunteers welcome
- Sponsor
- Spinifex Pharmaceuticals Pty Ltd
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg
The purpose of this clinical trial is to (1) evaluate the bioequivalence(BE) of GLA5PR GLARS-NF3 tablet 300mg administered regular diet relative to GLA5PR GLARS-NF1 tablet 300mg administered regular diet and (2) determine the…
- Trial name
- NCT02952937
- Testing
- GLA5PR GLARS-NF3 tablet 300mg, GLA5PR GLARS-NF1 tablet 300mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation